ASCO 2025 | Telisotuzumab adizutecan in c-Met–expressing refractory mCRC

ABB400, which goes by the name Temab-A now, is an antibody drug conjugate that’s directed against c-MET. We’ve known for many, many years that c-MET is oftentimes expressed in patients with metastatic colorectal cancer, and there’s a significant unmet need for novel therapeutics that can take that point of entry into cells to deliver potent chemotherapy. So what was presented here is a plan for a randomized control trial, which is now ongoing, that takes patients with the highest level of c-MET expression and randomizes them between this antibody drug conjugate, Temab-A, versus standard of care. And we’re very excited about this trial. I think this could potentially represent a breakthrough for patients one day. We, of course, need to do the work and do the trial and report out the results. But so far, we know that Temab-Ain our early experience is active. It generates a higher response rate than we would see with standard of care therapies. And by selecting for the highest level of c-MET expression, we think we can find those patients who are most likely to benefit. Thank you.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.